Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 3 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $85.14 (58.54% upside)

Current Analysts' Coverage Summary for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/19/2014Roth CapitalLower Price TargetBuy$121.50 -> $116.00ViewTweet This Rating  Share This Rating on StockTwits
11/5/2014ZacksDowngradeOutperform -> Neutral$60.10ViewTweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
9/25/2014Cantor FitzgeraldReiterated RatingHold$49.00ViewTweet This Rating  Share This Rating on StockTwits
2/21/2014Griffin SecuritiesSet Price Target$95.00ViewTweet This Rating  Share This Rating on StockTwits
2/2/2014Craig HallumSet Price Target$90.00ViewTweet This Rating  Share This Rating on StockTwits
3/25/2014Brinson PatrickSet Price Target$98.00ViewTweet This Rating  Share This Rating on StockTwits
4/28/2014Ned Davis ResearchUpgradeSell -> NeutralViewTweet This Rating  Share This Rating on StockTwits
2/24/2014Summer StreetBoost Price TargetBuy$78.00 -> $91.00ViewTweet This Rating  Share This Rating on StockTwits
2/13/2014TheStreetUpgradeHold -> BuyViewTweet This Rating  Share This Rating on StockTwits
2/10/2014MLV & Co Boost Price TargetBuy$82.00ViewTweet This Rating  Share This Rating on StockTwits
10/31/2013Brean CapitalDowngradeBuy -> Hold$45.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 11/27/2012 forward)